Heat shock proteins hsp27 and hsp70: Lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group study)

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1263-1266

  Ciocca, Daniel R ^a,f   Green, Stephanie ^b   Elledge, Richard M ^c   Clark, Gary M ^c   Pugh, Reginald ^c   Ravdin, Peter ^d   Lew, Danika ^b   Martino, Silvana ^e   Osborne, C Kent ^c  

^a Laboratorio de Reproduccion y Lactancia Mendoza   (Argentina)

^b Statistical Center   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Sterling Medical Office   (United States)

^e Westlake Compreh Breast Cancer Ctr   (United States)

^f Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; STATISTICS; TAMOXIFEN; TREATMENT FAILURE;

EID: 0031924597     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jordan, V. C. (ed.). Long-Term Tamoxifen Treatment for Breast Cancer. Madison, WI: University of Wisconsin Press, 1994.
2. Osborne, C. K., Wiebe, V. J., McGuire, W. L., Ciocca, D. R., and DeGregorio, M. W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J. Clin. Oncol., 10: 304-310, 1992.
3. Encarnacion, C. A., Ciocca, D. R., McGuire, W. L., Clark, C. M., Fuqua, S. A. W., and Osborne, C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat., 26: 237-246, 1993.
4. Catherine, W. H., Wolf, D. M., and Jordan, V. C. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol. Endocrinol., 9: 1053-1063, 1995.
5. Johnston, S. R. D., Saccani-Jotti, G., Smith, I. E., Salter, J., Newby, J., Coppen, M., Ebbs, S. R., and Dowsett, M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res., 55: 3331-3338, 1995.
6. Elledge, R., Green, S., Howes, L., Clark, G. M., Berardo, M., Allred, D. C., Pugh, R., Ciocca, D., Ravdin, P., O'Sullivan, J., Rivkin, S., Martino, S., and Osborne, C. K. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. J. Clin. Oncol., 15: 1916-1922, 1997.
7. Elledge, R., Green, S., Ciocca, D., Howes, L., Pugh, R., Clark, G., Ravdin, P., O'Sullivan, J., Langone, G., and Osborne, C. K. HER-2/neu expression does not predict response to tamoxifen in ER-positive metastatic breast cancer. Breast Cancer Res. Treat., 41: 289, 1996.
8. Ravdin, P. M., Green, S., Dorr, T. M., McGuire, W. L., Fabian, C., Pugh, R. P., Carter, R. D., Rivkin, S. E., Borst, J. R., Belt, R. J., Metch, B., and Osborne, C. K. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol., 10: 1284-1291, 1992.
9. Ciocca, D. R., Stati, A. O., and Amprino de Castro, M. M. Colocalization of estrogen and progesterone receptors with an estrogenregulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res. Treat., 16: 243-251, 1990.
10. Ciocca, D. R., Oesterreich, S., Chamness, G. C, McGuire, W. L., and Fuqua, S. A. W. Heat shock protein 27,000 (Hsp27): biological and clinical implications. J. Natl. Cancer Inst., 85: 1558-1570, 1993.
11. Cano, A., Coffer, A. I., Adatia, R., Millis, R., Rubens, R. D., and King, R. J. B, Histochemical studies with an estrogen-related protein in human breast tumors. Cancer Res., 46: 6475-6480, 1986.
12. Pratt, W. B., and Scherrer, L. C. Heat shock proteins and the cytoplasmic-nuclear trafficking of steroid receptors. In: V. K. Moudgil (ed.), Steroid Hormone Receptors: Basic and Clinical Aspects, pp. 215-246. Hormones in Health and Disease Series. Cambridge, MA: Birkhauser Boston, 1994.
13. Takahashi, S., Mikami, T., Watanabe, Y., Okazaki, M., Okazaki, Y., Okazaki, A., Sato, T., Asaishi., K., Hirata, K., Narimatsu, E., Mori, M., Sato. N., and Kikuchi, I. Correlation of heat shock protein 70 expression with estrogen receptor levels in invasive human breast cancer. Am. J. Clin. Pathol., 101: 519-525, 1994.
14. Chen, S., Prapapanich, V., Rimerman, R. A., Honor, B., and Smith, D. F. Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70. Mol. Endocrinol., 10: 682-693, 1996.
15. Ciocca, D. R., Fuqua, S. A. W., Lock-Lim, S., Toft, D. O., Welch, W. J., and McGuire, W. L. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res., 52: 3648-3654, 1992.
16. Ciocca, D. R., and Vargas-Roig, M. L. Heat shock proteins and drug resistance in breast cancer. In: S. Bernal (ed.), Drug Resistance in Oncology, pp. 167-190. New York: S. M. Marcel Dekker, 1997.
17. Oesterreich, S., Hilsenbeck, S. G., Ciocca, D. R., Allred, D. C., Clark, G. M., Chamness, G. C., Osborne, C. K., and Fuqua, S. A. W. The small heat shock protein hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin. Cancer Res., 2: 1199-1206, 1996.
18. Vargas-Roig, M. L., Fanelli, M. A., López, L. A., Gago, F. E., Tello, O., Aznar, J. C., and Ciocca, D. R. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect. Prev., 21: 441-451, 1997.
19. Vargas-Roig, L., Gago, F., Tello, O., and Ciocca, D. R. Heat shock protein hsp27 and drug resistance in breast cancer patients treated with induction chemotherapy. Proc. Am. Assoc. Cancer Res., 38: 389, 1997.
20. Margulis, B. A., and Welsh, M. Analysis of protein binding to heat shock protein 70 in pancreatic islet cells exposed to elevated temperatures or interleukin 1 β. J. Biol. Chem., 266: 9295-9298, 1991.
21. Zhu, Y., Tassi, L., Lane, W., and Mendelsohn, M. E. Specific binding of the transglutaminase, platelet factor XIII, to hsp27. J. Biol. Chem., 269: 22379-22384, 1994.
22. Iwaya, K., Tsuda, H., Fujita, S., Suzuki, M., and Hirohashi, S. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab. Invest., 72: 707-714, 1995.
23. Huot, J., Houle, F., Spitz, D. R., and Landry, J. Z. HSP27 phosphorylation-mediated resistance against fragmentation and cell death induced by oxidative stress. Cancer Res., 56: 273-279, 1996.
24. Mahvi, D. M., Carper, S. W., Yu, C. O., McCausland, T. A., and Storm, F. K. Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells. Endocrine, 4: 269-275, 1996.
25. Liu, F. F., Miller, N., Levin, W., Zanke, B., Cooper, B., Henry, M., Sherar, M. D., Pintilie, M., Hunt, J. W., and Hill, R. P. The potential role of hsp70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. Int. J. Hyperthermia, 12: 197-208, 1996.
26. r 27,000 heat shock protein (hsp27). Cell Growth Differ., 7: 1167-1174, 1996.
27. Agoff, S. N., Hou, J., Linzer, D. I. H., and Wu, B. Regulation of the human hsp70 promoter by p53. Science (Washington DC), 259: 84-87, 1993.
28. Tsutsumiishii, Y., Tadokoro, K., Hanaoka, F., and Tsuchida, N. Response of heat shock element within the human hsp70 promoter to mutated p53 genes. Cell Growth Differ., 6: 1-8, 1995.
29. Porter, W., Wang, F., Wang, W., Duan, R., and Safe, S. Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. Mol. Endocrinol., 10: 1371-1378, 1996.
30. r 24,000 in primary breast cancer and response to endocrine therapy. Eur. J. Cancer Clin. Oncol., 25: 641-643, 1989.
31. r 52,000, and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann. Oncol., 3: 71-77, 1992.
32. Hurlimann, J., Gebhard, S., and Gomez, F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathol. (Oxf.), 23: 239-248, 1993.